Oncolytics biotech inc. ONCY.US Overview
ONCY AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ONCY Current Performance
1.96%
Oncolytics biotech inc.
-0.91%
Avg of Sector
-0.13%
S&P500
ONCY Key Information
ONCY Revenue by Segments
Browsing restrictions can be lifted for a fee.
ONCY Net Income
Browsing restrictions can be lifted for a fee.
ONCY Cash Flow
Browsing restrictions can be lifted for a fee.
ONCY Profit Margin
Browsing restrictions can be lifted for a fee.
ONCY PE Ratio River
Browsing restrictions can be lifted for a fee.
ONCY Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
ONCY Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ONCY Profile
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Price of ONCY
ONCY FAQ
When is ONCY's latest earnings report released?
The most recent financial report for Oncolytics biotech inc. (ONCY) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ONCY's short-term business performance and financial health. For the latest updates on ONCY's earnings releases, visit this page regularly.
How much debt does ONCY have?
As of the end of the reporting period, Oncolytics biotech inc. (ONCY) had total debt of 1M, with a debt ratio of 0.05. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ONCY have?
At the end of the period, Oncolytics biotech inc. (ONCY) held Total Cash and Cash Equivalents of 15.3M, accounting for 0.78 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is ONCY's EPS continuing to grow?
According to the past four quarterly reports, Oncolytics biotech inc. (ONCY)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ONCY?
Oncolytics biotech inc. (ONCY)'s Free Cash Flow (FCF) for the period is -6.5M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 13.53% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ONCY?
The latest valuation data shows Oncolytics biotech inc. (ONCY) has a Price-To-Earnings (PE) ratio of -1.99 and a Price/Earnings-To-Growth (PEG) ratio of 0.09. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.